Opinions
Hugh Cleland, CFA
Medwell Capital Corp.
MWC-X
COMMENT
Jan 24, 2007
In phase 3 pivotal trial for secondary progressive MS and about a year away from getting data. Just got FDA approval to start trials in the US. Very high Risk and very high Reward.
$3.720
Stock price when the opinion was issued
Consumer Products
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.